454 pyrosequencing analysis on faecal samples from a randomized DBPC trial of colicky infants treated with Lactobacillus reuteri DSM 17938. – Cost Effective Supplements

454 pyrosequencing analysis on faecal samples from a randomized DBPC trial of colicky infants treated with Lactobacillus reuteri DSM 17938.

Quick navigation

Link
Conclusion
Supplements
Functions
Systems

Link to full study

http://www.ncbi.nlm.nih.gov/pubmed/23468874

Conclusion of this study

L. reuteri DSM 17938 did not affect the global composition of the microbiota. However, the increase of Bacteroidetes in the responder infants indicated that a decrease in colicky symptoms was linked to changes of the microbiota.